DE602006021408D1 - Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien - Google Patents

Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien

Info

Publication number
DE602006021408D1
DE602006021408D1 DE602006021408T DE602006021408T DE602006021408D1 DE 602006021408 D1 DE602006021408 D1 DE 602006021408D1 DE 602006021408 T DE602006021408 T DE 602006021408T DE 602006021408 T DE602006021408 T DE 602006021408T DE 602006021408 D1 DE602006021408 D1 DE 602006021408D1
Authority
DE
Germany
Prior art keywords
treatment
hpv
antigens
induced
neoplasia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006021408T
Other languages
English (en)
Inventor
Der Burg Sjoerd Hendricus Van
Rienk Offringa
Cornelis Johannes Melief
Theodorus Jozef Helmerhorst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leids Universitair Medisch Centrum LUMC
Original Assignee
Leids Universitair Medisch Centrum LUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leids Universitair Medisch Centrum LUMC filed Critical Leids Universitair Medisch Centrum LUMC
Publication of DE602006021408D1 publication Critical patent/DE602006021408D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602006021408T 2005-04-27 2006-04-25 Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien Active DE602006021408D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05103447 2005-04-27
PCT/NL2006/050099 WO2006115413A2 (en) 2005-04-27 2006-04-25 Methods and means for the treatment of hpv induced intraepithelial neoplasias

Publications (1)

Publication Number Publication Date
DE602006021408D1 true DE602006021408D1 (de) 2011-06-01

Family

ID=35583560

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006021408T Active DE602006021408D1 (de) 2005-04-27 2006-04-25 Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien

Country Status (10)

Country Link
US (2) US7807369B2 (de)
EP (2) EP2289516B1 (de)
JP (1) JP5106384B2 (de)
CN (1) CN101189014A (de)
AT (1) ATE506063T1 (de)
AU (1) AU2006240561B2 (de)
CA (1) CA2609927A1 (de)
DE (1) DE602006021408D1 (de)
ES (1) ES2363247T3 (de)
WO (1) WO2006115413A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530362A (ja) * 2007-05-31 2010-09-09 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク 皮内ｈｐｖペプチドワクチン接種
WO2011062147A1 (ja) * 2009-11-17 2011-05-26 国立大学法人 岡山大学 歯髄細胞から象牙芽細胞への分化誘導方法
US8802433B2 (en) 2009-12-03 2014-08-12 Aureo Co., Ltd. Macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages
US20150310128A1 (en) * 2014-04-28 2015-10-29 Elwha Llc Methods, systems, and devices for machines and machine states that manage relation data for modification of documents based on various corpora and/or modification data
WO2017015504A1 (en) * 2015-07-21 2017-01-26 Scheibel Steven Frederick Treatment and prevention of anal conditions
AU2016323770A1 (en) 2015-09-16 2018-03-29 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
CN108430505A (zh) 2015-11-18 2018-08-21 免疫疫苗技术有限公司 包括聚肌胞苷酸多核苷酸佐剂和基于脂质的佐剂的辅助系统以及无水疫苗组合物
CN106632694B (zh) * 2017-01-24 2021-02-12 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
ES2955884T3 (es) 2017-03-15 2023-12-07 Dfb Soria Llc Terapia tópica para el tratamiento de malignidades de la piel con nanoparticulas de taxanos
WO2018170210A1 (en) * 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
RU2682783C2 (ru) * 2017-06-14 2019-03-21 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ ОММ" Минздрава России) Способ лечения цервикальных интраэпителиальных неоплазий i степени, ассоциированных с впч высокого онкогенного риска, с использованием кавитированного раствора панавира
WO2019178024A1 (en) 2018-03-16 2019-09-19 Dfb Soria, Llc Topical therapy for the treatment of cervical intraepithelial neoplasia (cin) and cervical cancer using nanoparticles of taxanes
CN109614613B (zh) 2018-11-30 2020-07-31 北京市商汤科技开发有限公司 图像的描述语句定位方法及装置、电子设备和存储介质
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CN111905201A (zh) * 2020-08-18 2020-11-10 珠海市索利达医疗器械有限公司 一种生殖道hr-hpv治疗设备
CN114409744B (zh) * 2022-03-29 2022-10-04 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1002110T3 (da) * 1997-08-05 2003-05-26 Stressgen Biotechnologies Corp Immunsvar mod HPV-antigener fremkaldt af sammensætninger, som omfatter et HPV-antigen og et stressprotein eller en ekspressionsvektor i stand til at ekspressere disse proteiner
CZ20012446A3 (cs) * 1999-01-08 2002-01-16 3M Innovative Properties Company Farmaceutický prostředek pro léčbu onemocnění sliznice
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
KR100919266B1 (ko) * 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법
AU2002219711B8 (en) 2000-12-08 2006-03-02 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
EP1288292A1 (de) 2001-08-31 2003-03-05 Leids Universitair Medisch Centrum Lange Peptiden die 22-40 Aminosäuren enthalten und die eine immunspezifische Immunantwort induzieren
GB0105606D0 (en) 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
PT1531843E (pt) * 2001-12-17 2011-10-27 Zymogenetics Inc Método para tratar o cancro cervical
CN1845736A (zh) * 2003-09-02 2006-10-11 3M创新有限公司 治疗粘膜相关病症的方法
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma

Also Published As

Publication number Publication date
CN101189014A (zh) 2008-05-28
AU2006240561B2 (en) 2011-06-02
WO2006115413A2 (en) 2006-11-02
ES2363247T3 (es) 2011-07-28
US7807369B2 (en) 2010-10-05
US20110008287A1 (en) 2011-01-13
JP5106384B2 (ja) 2012-12-26
CA2609927A1 (en) 2006-11-02
EP2289516B1 (de) 2014-01-08
EP1874312A2 (de) 2008-01-09
US20090060870A1 (en) 2009-03-05
AU2006240561A1 (en) 2006-11-02
EP1874312B1 (de) 2011-04-20
EP2289516A1 (de) 2011-03-02
JP2008539228A (ja) 2008-11-13
ATE506063T1 (de) 2011-05-15
WO2006115413A3 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
ATE506063T1 (de) Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
HK1115192A1 (en) Methods and compositions for diagnosis and treatment of influenza
NZ590890A (en) Neutralizing anti-influenza a virus antibodies and uses thereof
RU2017132160A (ru) Антитела к pd-l1 и их применение для усиления функции t-клеток
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
NO20066078L (no) Metode for fremstilling av Entecavir og nye mellomprodukter derav via karbon-silisium oksidasjon
WO2007121894A3 (en) Hpv-18-based papillomavirus vaccine
EP2275816A3 (de) Verfahren zur Identifizierung von Polypeptid-targets und ihre Verwendung zur Behandlung von Immunerkrankungen
JP2015529197A5 (de)
WO2005120166A3 (en) Antibodies for selective apoptosis of cells
MX2019001767A (es) Anticuerpos monoclonales que se unen al dominio de union a lipidos de la proteina de la capside del virus de la hepatitis c (vhc).
WO2009001867A1 (ja) 高リスク群ヒトパピローマウイルスに対する交差性中和抗体を誘導するワクチン抗原
WO2010070052A3 (en) Immunogenic polypeptides comprising a scaffold polypeptide and a l2 polypeptide or a fragment thereof
NZ611168A (en) Monoclonal antibody recognizing human papilloma virus (hpv) l2 protein and method for measuring hpv-neutralizing antibody titer using the same
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
EA200701092A1 (ru) Антигенные эпитопы интерлейкина-21, связанные с ними антитела и их применение в медицине
CY1110098T1 (el) Βιομηχανικη μεθοδος για τη παρασκευη της γαμμα-λακτονης του 17-υδροξυ-6-βητα,7-βητα, 15-βητα,16-βητα-δις-μεθυλενο-3-οξο-17-αλφα πρεγκν-4-ενο-21-καρβοξυλικου οξεος και ενδιαμεσα κλειδια για την μεθοδο αυτη
JP2018525453A5 (de)
WO2010056889A3 (en) Use of an antibody and a rare-earth based crystal
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
NO20070195L (no) Vaksine mot HPV16 og HPV18 og minst en annen HPV-type valgt fra HPV31, 45 eller 52
WO2007002587A3 (en) Inhibitors of epstein barr virus nuclear antigen 1
WO2022204713A3 (en) Antibodies to sars-cov-2
NO20063603L (no) Fremgangsmate for vaksinering mot BVDV-infeksjon i testikkel
WO2004046182A3 (en) Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases